The work of the University of Pittsburgh School of Medicine researchers is detailed in a paper published recently in EBioMedicine, which is published by the Lancet.
Delivery of the vaccine involved a microneedle array to increase potency. The fingertip-sized patch uses dissolvable needles – made of sugar and protein pieces – to deliver the virus’s spike protein into the skin, eliciting an immune response.
Meanwhile, Janssen Pharmaceutical Co, a division of Johnson & Johnson, announced it will partner with Beth Israel Deaconess Medical Center (BIDMC) to support coronavirus vaccine development. Janssen has started preclinical testing of several projects in its work with Dr. Dan Barouch at BIDMC.
They expect to identify a COVID-19 vaccine candidate for clinical trials by the end of the year.